Celmatix, a biotech firm specializing in women’s health, has announced progress in their oral fertility drug program. The program’s primary objective is to substitute follicle stimulating hormone (FSH) injections, commonly used in in vitro fertilization (IVF) and egg freezing protocols, with an oral alternative. This New York-based company aims to make ovulation induction more efficient, specifically for women with conditions like polycystic…
Embie Clinic is on a mission to optimize fertility treatments with personalized, connected care. Its platform empowers fertility clinics worldwide with real-time insights while reducing administrative burdens. As a top patient-facing fertility treatment app, Embie supports 48K+ women across 120 countries today. New research presented by Embie Clinic at the 39th Annual European Society of Human Reproduction and Embryology (ESHRE) meeting today…
May Health, a clinical-stage medical device company focusing on polycystic ovary syndrome (PCOS), presented promising results from the ULTRA-EU and ULTRA-US feasibility clinical trials for its Ovarian Rebalancing treatment at the 39th Annual European Society of Human Reproduction and Embryology (ESHRE) meeting. The trials demonstrated the treatment’s safety and effectiveness in inducing ovulation in women with PCOS-related infertility. The company also received…
Israeli fertility company Fairtility has announced the launch of CHLOE OQ, a tool aimed at fertility preservation, at the 39th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Copenhagen today. The newly unveiled tool provides Oocyte Quality Insights, predicting the potential of an oocyte (egg cell) to develop into the blastocyst stage after fertilization, a crucial aspect…
Oova, a women’s health and fertility startup, has secured $10.3 million in Series A funding for its at-home fertility tracking approach. The company offers the Oova Kit, an FDA-registered at-home urine test that measures luteinizing hormone and progesterone. The test provides personalized analytics and real-time action plans, helping women identify fertile days and confirm ovulation. Although focused on fertility for now, the…
Toronto-based Twig Fertility, a fertility care platform, has recently concluded its Series A financing round, securing $8M in funding. The round was led by Rhino Ventures, a venture capital firm specialized in healthcare technology investments. This financial backing marks an important milestone for Twig Fertility, enabling the company to advance its platform, expand services, and provide support to individuals and couples on…
According to studies, 50% of couples are expected to rely on IVF for conception by 2045. Demand for IVF and related fertility services is rapidly growing around the world, yet – although treatments are available – many struggle to access the care they need on their family planning journey. This is especially true in emerging markets, where the development of new technologies…
Mate Fertility’s mission is to make high quality fertility treatment affordable, accessible and consistent throughout the United States by finding fertility deserts and upskilling OB/GYN partner providers under REI supervision to practice at the top of their license while providing best in class experience to patients. Only a couple of weeks ago in March we reported on the company’s fundraising and crowdfunding…
